Refine by
Cancerous Target Articles & Analysis
129 news found
Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. ...
Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. Such APIs come in a wide range of types: chemotherapeutic, targeted, immunotherapeutic, hormone therapeutic. The APIs in chemotherapy work by interfering with the cell division mechanism to suppress cancer ...
It is well established that oncogenic alterations, such as mutations and fusions, can lead to malignant cellular growth that results in cancer. While approved targeted agents are available to treat several types of oncogenic mutations, patients whose cancers harbor oncogene amplification typically do not derive the same benefit. Oncogenes can be ...
Antitumor therapy now focuses on targeting enzymes that are abnormally expressed in cancer cells. Three irreversible and numerous reversible enzymatic reactions can occur along the glycolytic pathway. The metabolic reprogramming of cancer involves modifications in the glycolytic pathway's enzymatic response in cancer cells. ...
Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1 designed to improve on first generation EZH2 inhibitors via increased potency, longer residence time on target and a longer half-life. The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics ...
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S. “The FDA approval of ORSERDU marks the first ever therapy for ER+, HER2- advanced or metastatic breast cancer ...
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. ...
This improved outlook comes amid the company’s potential blockbuster drugs tracking ahead of schedule and targeted investments in Research and Development (R&D) replenishing its pharmaceutical development pipeline. ...
ByBayer AG
It provides protection for both autologous (patient-derived) and allogeneic (off-the-shelf) immune cell products that carry the TAG-72 CAR. TAG-72 a well-validated target, highly expressed on a range of adenocarcinomas including ovarian and gastric cancers. Issuance of the patent is an important milestone in underpinning the development of new treatments for ...
” iBio’s RubrYc Discovery Engine is designed to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. It uses a combination of a proprietary epitope steering technology, a specialized antibody library, and AI-powered antibody optimization to quickly identify ...
(Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, ...
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers ...
LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. To view LIXTE Biotechnology Holdings' presentation at the Planet MicroCap conference, register in advance at: https://planetmicrocapshowcase.com/signup The ...
(NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. ...
Synaffix continues to build its partnered pipeline as technology out-licensing is the primary focus of its corporate strategy to deliver best-in-class targeted cancer therapeutics from partner antibodies. ...
BNCT is a targeted radiation cancer therapy in which neutron beams interact with a boron-bearing compound, taken up selectively by tumors, to create DNA-damaging alpha particles within the tumor cells, sparing neighboring, healthy tissue. ...